Denosumab is indicated for treating osteoporosis in postmenopausal women, preventing skeletal-related complications in cancer ...

Prolia® is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily ...

Please provide your email address to receive an email when new articles are posted on . Hypocalcemia risk increased with worsening CKD stages, particularly for patients on dialysis. Emergently treated ...

Treatment with denosumab vs oral bisphosphonates was associated with increased risks for MACE and hypocalcemia in dialysis-dependent patients with osteoporosis.

Teva shared that the Food and Drug Administration has accepted, and the European Medicines Agency has validated, applications for TVB-009P, a biosimilar candidate to Amgen’s Prolia (denosumab). Both ...

Longer durations of denosumab treatment improved the probability of achieving target T-scores at the total hip and lumbar spine in postmenopausal women with osteoporosis. Denosumab treatment ...

UK headquartered Hikma Pharmaceuticals, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc, have announced ...

Credit: Celltrion. The denosumab biosimilars Stoboclo and Osenvelt have the same indications as the reference products Prolia and Xgeva, respectively. Patient support and financial assistance are ...

The Food and Drug Administration (FDA) has approved Stoboclo ® (denosumab-bmwo), a biosimilar to Prolia ® (denosumab), and Osenvelt ® (denosumab-bmwo), a biosimilar to Xgeva ® (denosumab). Stoboclo is ...

Findings showed denosumab-qbde demonstrated comparable quality, efficacy, safety, and immunogenicity to the reference product. Enoby is approved to treat postmenopausal women with osteoporosis at high ...

Adding denosumab to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor (HR)-positive breast cancer, according to results ...

Credit: Celltrion. The FDA originally approved Stoboclo and Osenvelt as biosimilars in March 2025. The interchangeability designation allows Stoboclo and Osenvelt to be substituted at the pharmacy for ...